--- title: "Arthrex Releases TightRope® SB All-Suture Implant for ACL Fixation" type: "News" locale: "en" url: "https://longbridge.com/en/news/277081966.md" description: "Arthrex has launched the TightRope® SB implant, the first all-suture device for ACL reconstruction, enhancing minimally invasive surgical options. This innovative implant, which has already been used in nearly 2,000 procedures, eliminates metal components while providing strong fixation and flexibility for surgeons. The TightRope SB aims to improve knee stability and range of motion, reflecting advancements in ACL surgery. It received recognition at the Edison Awards for its design and impact on patient care. Arthrex continues to lead in minimally invasive surgical technology and innovation." datetime: "2026-02-26T18:10:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277081966.md) - [en](https://longbridge.com/en/news/277081966.md) - [zh-HK](https://longbridge.com/zh-HK/news/277081966.md) generator: "portal-rs" --- # Arthrex Releases TightRope® SB All-Suture Implant for ACL Fixation ***Facilitates Least Invasive All-Inside, No Metal ACL Reconstruction*** NAPLES, Fla., Feb. 26, 2026 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, announced that it has released the TightRope® SB implant, the first device on the market for anterior cruciate ligament (ACL) reconstruction using all-suture, soft-button technology. To date, nearly two thousand implants have been used in procedures across the U.S. ACL reconstruction is one of the most performed orthopedic procedures worldwide, helping patients across all activity levels—from elite athletes to active adults—return to stability, confidence and movement. The TightRope® SB implant represents the evolution of Arthrex ACL technology, offering a fully all‑suture solution while maintaining the procedural flexibility and reproducibility surgeons expect. By eliminating rigid materials and preserving strong, adjustable fixation, the device expands graft-fixation options for both ACL reconstruction and repair. This less invasive approach supports improved knee stability and range of motion,1,2 while eliminating the presence of metal implants. "We look forward to seeing how patients benefit from this revolutionary solution for ACL reconstruction," said Arthrex Knee Ligament Senior Group Product Manager Justin Boyle. "The TightRope SB builds on Arthrex's foundation of knee ligament innovation and reflects how ACL surgery continues to evolve." The all-suture, soft-button technology used in the TightRope SB implant offers high-strength fixation and features a flat-tape loop that holds the new ligament in place.2 The implant is also radiopaque, which helps surgeons confirm its position during and after surgery. The implant is available in a variety of configurations to support ACL reconstruction using all graft types as well as ACL primary repair procedures. CU Anschutz Orthopedics and UCHealth surgeon Rachel M. Frank, MD (Aurora, Colorado), completed the first cases with the TightRope SB implant in June 2025. Both cases were QuadLink™ all-inside ACL reconstructions with the *Internal*Brace™ technique. "The TightRope SB implant introduces a metal-free, screw-free option for ACL reconstruction fixation," said Dr. Frank. "The adjustable, all-suture construct provides intraoperative flexibility in graft tensioning and a low-profile footprint. Together, these design features reflect an important step forward in ACL fixation, with continued evaluation underway to assess clinical outcomes." In April 2025, the TightRope SB implant received gold in the Healthcare Environment and Patient Care Solutions category at the 38th annual Edison Awards. "Winning gold at the Edison Awards is a powerful validation of our shared commitment to innovation and our mission of Helping Surgeons Treat Their Patients Better®," said Boyle. "This recognition reflects the purpose‑driven design behind TightRope SB and its role in advancing ACL reconstruction." For more information, downloadable multimedia assets and interview requests for subject matter experts, contact Arthrex Media Relations. **About Arthrex** Arthrex, headquartered in Naples, Florida, is a global medical device company and leader in multispecialty minimally invasive surgical technology innovation, scientific research, manufacturing and medical education. The company has pioneered the field of arthroscopy and sports medicine and develops more than 1,000 new products and related procedures annually to advance minimally invasive surgery for orthopedics, trauma, and spine, in addition to arthroplasty, cardiothoracic, and biologic innovations. Arthrex also specializes in the latest 4K multispecialty surgical visualization and OR integration technology solutions. For more information, visit Arthrex.com. **References** 1. van der List JP, DiFelice GS. Primary repair of the anterior cruciate ligament: A paradigm shift. Surgeon. 2017;15(3):161-168. doi:10.1016/j.surge.2016.09.006 2. Arthrex, Inc. Data on file (APT-07399). Naples, FL; 2025. The *Internal*Brace surgical technique is intended only to augment the primary repair/reconstruction by expanding the area of tissue approximation during the healing period and is not intended as a replacement for the native ligament. The *Internal*Brace technique is for use during soft tissue-to-bone fixation procedures and is not cleared for bone-to-bone fixation. View original content to download multimedia:https://www.prnewswire.com/news-releases/arthrex-releases-tightrope-sb-all-suture-implant-for-acl-fixation-302698724.html SOURCE Arthrex, Inc. ### Related Stocks - [ARTHQ.US](https://longbridge.com/en/quote/ARTHQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [ARTH.US](https://longbridge.com/en/quote/ARTH.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [ARQT.US](https://longbridge.com/en/quote/ARQT.US.md) ## Related News & Research - [Arcutis EVP, Chief Legal Officer Masaru Matsuda sells 9,989 shares for $249,861](https://longbridge.com/en/news/298654373.md) - [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md) - [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md) - [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md) - [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**